Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.

British journal of clinical pharmacology - 1 May 1990

Brunel P, Lecaillon J B, Guyene T T, Imhof P, Ménard J

Abstract excerpt

1. Cadralazine is a new antihypertensive agent which causes peripheral vasodilation, probably mediated by a hydrazinopyridazine metabolite. 2. The possible influence of acetylator status on the pharmacokinetics and haemodynamics of the drug was studied in six fast and six slow acetylators over a period of 24 h after administration of a single 10 mg oral dose. 3. There were no differences between the two groups in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Antihypertensive Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Blood Pressure

Share to Heart Rate

Share to Hemodynamics

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 2190629
DOI: 10.1111/j.1365-2125.1990.tb03672.x
PMCID: PMC1380148

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.PMID 2190629Read ↗

Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.Semantic proximity Read ↗

Plasma concentration and acetylator phenotype determine response to oral hydralazine.Semantic proximity Read ↗

Pharmacokinetics, acetylation-deacetylation, renal clearance, and protein binding of sulphamerazine, N4-acetylsulphamerazine, and N4-trideuteroacetylsulphamerazine in 'fast' and 'slow' acetylators.Semantic proximity Read ↗

N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.Semantic proximity Read ↗

Acetylation phenotype in hypertensive patients.Semantic proximity Read ↗

Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.Semantic proximity Read ↗

Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects.Semantic proximity Read ↗

The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits.Semantic proximity Read ↗

Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.Semantic proximity Read ↗

Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators.Semantic proximity Read ↗

Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.Semantic proximity Read ↗

[Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.